CP Guojian Pharmaceutical

Executive Summary

CP Guojian Pharmaceutical, a subsidiary of Shanghai Pharmaceutical, is a Chinese biopharmaceutical company focused on innovative biologics and biosimilars for oncology and immunology. With a Phase 3-stage pipeline, the company is advancing several candidates toward regulatory submission. As a public entity under a major pharma group, it benefits from strong manufacturing capabilities and market access in China. The near-term outlook includes potential pivotal data readouts and NDA filings that could drive value.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Phase 3 Trial Results for Lead Biosimilar75% success
• Q4 2026NDA Submission for Novel Biologic Candidate65% success
• TBDEx-China Licensing Agreement for Pipeline Asset40% success